Long Noncoding RNAs in Brain Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Neurobiology and Clinical Neuroscience".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 104

Special Issue Editor


E-Mail Website
Guest Editor
Department of Psychiatry, Washington University in St. Louis, St. Louis, MI 63110, USA
Interests: lncRNA biology; neurodegeneration; translational oncology; carcinogenesis; cancer genomics

Special Issue Information

Dear Colleagues,

Long non-coding RNAs (lncRNAs) are fascinating molecules that shape how our brains work. They do not make proteins, but they control how genes are turned on and off, how neurons grow and connect, and how the brain adapts to changes. When lncRNAs go wrong, they can cause many different brain diseases. For example, in Alzheimer’s, Parkinson’s, Huntington’s, and ALS, lncRNAs affect the buildup of toxic proteins that damage brain cells. In schizophrenia, bipolar disorder, and depression, lncRNAs influence how neurons communicate and respond to stress. In brain cancers such as glioblastoma and medulloblastoma, lncRNAs help tumor cells grow, spread, and resist drugs. In autism and intellectual disabilities, lncRNAs affect how the brain develops and learns. By studying lncRNAs, we can learn more about these conditions and find new ways to diagnose and treat them. We can also try to change the activity of specific lncRNAs that are involved in disease processes and see if we can improve the outcomes. However, there is still much to discover about how lncRNAs work and how to target them safely and effectively. The goal of this Special Issue is to share the latest research on lncRNAs and brain diseases, in particular explaining how lncRNAs regulate the brain at the molecular level. We encourage submissions on how lncRNAs can be used as markers and tools for these diseases and what the challenges and opportunities are for the future of lncRNA research.

Dr. Arun Renganathan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • long non-coding RNAs
  • brain diseases
  • neurodegenerative diseases
  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
  • amyotrophic lateral sclerosis
  • psychiatric disorders
  • brain tumors
  • neurodevelopmental disorders

Published Papers

This special issue is now open for submission.
Back to TopTop